PhD Student of Clinical Psychology, Department of Psychology and Educational, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Journal Title: Archives of Neuroscience - Year 2017, Vol 4, Issue 4
Abstract
Background: Generalized anxiety disorder (GAD) is known as the most prevalent anxiety disorder. Saffron has been previously approved as an effective adjuvant therapy in depression and might alleviate GAD symptoms. Methods: In the current double blind randomized controlled trial, 40 patients with mild to moderate GAD, diagnosed according to the diagnostic and statistical manual of mental disorders-V (DSM-V) and received sertraline were randomly assigned to the saffron receiving group (450 mg, n = 20) or placebo taking patients (n = 20). Interventions were administered as an add-on therapy to sertraline on a daily bases for 6 weeks. In addition to assessing anthropometric, demographic data, and dietary intakes of patients, a 14-item Hamilton anxiety rating scale (HAM-A) was used to assess the effect of treatment. Results: The mean (SD) of age was 29.65 (8.45) and 32.40 (6.74) years in the Saffron and placebo groups, respectively. Applying ANCOVA models adjusted for age, baseline energy intake, HAM-A total score, and weight changes from baseline to the 6th week, showed that at the end of the 6th week, saffron treated patients had a significantly lower mean HAM-A score compared to placebo group (2.95 vs. 5.05; P value = 0.005). Furthermore, within the group analysis it was shown that the total HAM-A score significantly declined in both groups (P value ≤ 0.000). Measuring changes in the HAM-A total score, relative to the baseline, following adjustment of ANCOVA models, showed that saffron was more effective than the placebo in reducing the mean HAM-A score of patients (-17.25 ± 2.67 vs. -15.35 ± 2.30; P value = 0.029). The side effects were tolerable and did not result in discontinuation of the supplementation. Conclusions: Saffron as a sertraline add-on therapy may attenuate GAD symptoms. However, more randomized clinical trials with a larger sample size and longer duration of follow-up are needed to confirm this effect.
Authors and Affiliations
Nasibe Jafarnia, Zeinab Ghorbani, Morteza Nokhostin, Azadeh Manayi, Saeedeh Nourimajd, Soodeh Razeghi Jahromi
Keywords
Related Articles
- EP ID EP292610
- DOI 10.5812/archneurosci.14332
- Views 98
- Downloads 0
The Relationship Between Executive Functions with Reading Difficulties in Children with Specific Learning Disorder
Background: Determining the impact of executive dysfunction on reading defects in children with reading and learning disabilities can tremenddously help their treatment. In the recent decade, the role of executive functi...
RETRACTED ARTICLE: Cromakalim, a Potassium Channel Opener, Ameliorates Organophosphate- and Carbamate-Induced Seizures in Mice
Background: Organophosphates (OPs) and carbamates are acetylcholine esterase inhibitors (AChEIs), which can cause seizure and death. The anticonvulsant properties of potassium channel openers, including cromakalim, have...
A Theoretical Framework to Explain the Superior Cognitive Competence in Humans: A Role for the Division of Labour in the Brain
Parallel mathematical descriptions of behavioral structures across species are not necessarily associated with parallel cognitive outcomes. The present discussion provides an anal...
A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement
The current knowledge on how to use stem cells therapeutically for improving motor function in patients with cerebral palsy is growing. The present review aimed at assessing clinical trials related to beneficial effects...
SCN1A and ABCB1 Polymorphisms in Epilepsy
Genetic variability in drug metabolism affects its treatment with anti epilepsy drugs (AEDs). Allelic variations in genes include SCN1A and ABCB1. Encoding the AEDs’ target and drug transport proteins may affect the effi...